harmonet 75 mikrogramov/20 mikrogramov obložene tablete
pfizer europe ma eeig - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol
zycortal
dechra regulatory b.v. - desoksikorton pivalat - kortikosteroidi za sistemsko uporabo - psi - za uporabo kot nadomestno zdravljenje za mineralocorticoid pomanjkljivost pri psih s primarno hypoadrenocorticism (addison bolezen).
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
provera 100 mg tablete
pfizer luxembourg sarl - medroksiprogesteronacetat - tableta - medroksiprogesteronacetat 100 mg / 1 tableta - medroksiprogesteron
provera 500 mg tablete
pfizer luxembourg sarl - medroksiprogesteronacetat - tableta - medroksiprogesteronacetat 500 mg / 1 tableta - medroksiprogesteron
fulvestrant teva 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
teva b.v. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant
faslodex
astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.
sogroya
novo nordisk a/s - somapacitan - rast - hipofize in hipotalamični hormoni in analogi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).
fulvestrant aptapharma 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant
fulvestrant fresenius kabi 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant